Monday, January 31, 2000
Following the third set of disappointing Phase III results
with British Biotech plc's marimastat oral matrix metalloproteinase inhibitor
(MMPI), both patients in the company's ongoing trials as well as its shareholders
may be wondering why additional resources - both human and financial - are being
devoted to continued development of the compound. The reason is that researchers
believe that MMPIs will work better in earlier-stage patients than in the late-stage
patients for whom results have so far been available.
Thus British Biotech (LSE:BBG; BBIOY, Oxford, U.K.) is determined
to see the results of four additional ongoing Phase III studies that are nearing
completion, two of which- in small cell lung cancer - it believes represent
patients more likely to respond to marimastat. Results are expected this year
from both, as well as from Phase III studies of marimastat to treat glioblastoma
and ovarian cancer.